S&P 500
5,844.61
-1.6%
-95.85
DJI
41,860.44
-1.9%
-816.80
NASDAQ
$18,872.64
-1.4%
-$270.07
Bitcoin
108,272.00
+1.5%
+1,640.76
AAPL
$202.42
-2.1%
-$4.44
AMZN
$201.35
-1.3%
-$2.72
GOOG
$170.25
+3.0%
+$4.93
META
$635.69
-0.2%
-$1.41
MSFT
$453.22
-1.1%
-$4.95
NVDA
$131.94
-1.8%
-$2.44
TSLA
$334.80
-2.6%
-$9.02
CytoDyn (OTC: CYDY)
$0.34
(-12.3%)
-$0.05
Price as of May 21, 2025, 3:53 p.m. ET
CytoDyn Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CytoDyn Company Info
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
News & Analysis
Featured Article
3 Biotechs to Avoid Like the Plague in July
Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.
Zhiyuan Sun | Jul 6, 2021
Featured Article
What's Behind This Wild-Card Coronavirus Stock?
Failure is not an option for this small-cap biotech developing a COVID-19 treatment.
Zhiyuan Sun | Jun 8, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.